Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for Eysuvis

Kala Pharmaceuticals announced that the largest Pharmacy Benefit Manager in the United States has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 1, 2022. This adds 28.5 million people to Eysuvis coverage, bringing total commercial coverage to 155.3 million, or 92% of total commercial lives.

Also today, Kala announced that Humana, one of the largest Medicare health plans in the United States, has added Eysuvis as a "Preferred Brand" on its Medicare formularies, effective June 1, 2022. This adds approximately 7 million Medicare lives to Eysuvis coverage, bringing total Eysuvis Medicare coverage to 14.1 million lives, or approximately 30% of all Medicare lives.

“We are excited to announce this additional payer coverage, which brings our commercial access to 92% of covered lives and doubles our Medicare Part D coverage. This is an important step toward our goal of securing broad commercial and Medicare access for Eysuvis and we expect the additional coverage will translate into higher prescription fulfillment rates and accelerated growth,” said Todd Bazemore, President and Chief Operating Officer of Kala Pharmaceuticals. “Earlier this year, we secured coverage with several large commercial and Medicare Part D plans and, together with these additions, we have now achieved total Eysuvis coverage for more than 169 million lives. We continue to engage with other commercial and Medicare Part D health plans and anticipate further formulary additions in 2022.”